O	0	5	Three
O	6	10	dose
O	11	19	regimens
O	20	22	of
B-intervention	23	34	fulvestrant
O	35	37	in
O	38	52	postmenopausal
B-ethinicity	53	61	Japanese
B-eligibility	62	67	women
I-eligibility	68	72	with
I-eligibility	73	81	advanced
I-eligibility	82	88	breast
I-eligibility	89	95	cancer
O	95	96	:
O	97	104	results
O	105	109	from
O	110	111	a
O	112	118	double
O	118	119	-
O	119	124	blind
O	124	125	,
O	126	131	phase
O	132	134	II
O	135	146	comparative
O	147	152	study
O	153	154	(
O	154	161	FINDER1
O	161	162	)
O	162	163	.

O	164	171	FINDER1
O	172	180	compared
O	181	189	efficacy
O	189	190	,
O	191	203	tolerability
O	204	207	and
O	208	224	pharmacokinetics
O	225	226	(
O	226	228	PK
O	228	229	)
O	230	232	of
O	233	238	three
O	239	250	fulvestrant
O	251	255	dose
O	256	264	regimens
O	265	267	in
O	268	282	postmenopausal
O	283	291	Japanese
O	292	297	women
O	298	302	with
O	303	311	estrogen
O	312	320	receptor
O	321	322	(
O	322	324	ER
O	324	325	)
O	325	326	-
O	326	334	positive
O	335	342	locally
O	343	351	advanced
O	351	352	/
O	352	362	metastatic
O	363	369	breast
O	370	376	cancer
O	377	386	recurring
O	387	389	or
O	390	401	progressing
O	402	407	after
O	408	413	prior
O	414	423	endocrine
O	424	431	therapy
O	431	432	.

O	433	436	The
O	437	444	primary
O	445	448	end
O	449	454	point
O	455	457	of
O	458	462	this
O	463	473	randomised
O	473	474	,
O	475	486	multicentre
O	486	487	,
O	488	493	phase
O	494	496	II
O	497	502	study
O	503	506	was
B-outcome-Measure	507	516	objective
I-outcome-Measure	517	525	response
I-outcome-Measure	526	530	rate
I-outcome-Measure	531	532	(
I-outcome-Measure	532	535	ORR
I-outcome-Measure	535	536	)
O	537	540	and
O	541	544	the
O	545	554	secondary
O	555	558	end
O	559	565	points
O	566	574	included
B-outcome-Measure	575	579	time
I-outcome-Measure	580	582	to
I-outcome-Measure	583	594	progression
I-outcome-Measure	595	596	(
I-outcome-Measure	596	599	TTP
I-outcome-Measure	599	600	)
O	600	601	,
B-outcome-Measure	602	610	clinical
I-outcome-Measure	611	618	benefit
I-outcome-Measure	619	623	rate
I-outcome-Measure	624	625	(
I-outcome-Measure	625	628	CBR
I-outcome-Measure	628	629	)
O	629	630	,
B-outcome-Measure	631	633	PK
I-outcome-Measure	634	642	profiles
O	643	646	and
B-outcome-Measure	647	659	tolerability
O	659	660	.

O	661	675	Postmenopausal
O	676	681	women
O	682	686	with
O	687	689	ER
O	689	690	-
O	690	698	positive
O	699	707	advanced
O	708	714	breast
O	715	721	cancer
O	722	726	were
O	727	737	randomised
O	738	740	to
O	741	743	28
O	743	744	-
O	744	747	day
O	748	754	cycles
O	755	757	of
O	758	769	fulvestrant
O	770	778	approved
O	779	783	dose
O	784	785	(
O	785	787	AD
O	787	788	)
O	788	789	,
O	790	797	loading
O	798	802	dose
O	803	804	(
O	804	806	LD
O	806	807	)
O	808	810	or
O	811	815	high
O	816	820	dose
O	821	822	(
O	822	824	HD
O	824	825	)
O	826	831	until
O	832	839	disease
O	840	851	progression
O	851	852	.

B-total-participants	853	860	Hundred
I-total-participants	861	864	and
I-total-participants	865	870	forty
I-total-participants	870	871	-
I-total-participants	871	876	three
O	877	885	patients
O	886	887	(
O	887	893	median
O	894	897	age
B-age	898	900	61
I-age	901	906	years
O	906	907	)
O	908	916	received
B-intervention	917	928	fulvestrant
I-intervention	929	931	AD
O	932	933	(
O	933	934	n
O	935	936	=
B-intervention-participants	937	939	45
O	939	940	)
O	940	941	,
B-intervention	942	944	LD
O	945	946	(
O	946	947	n
O	948	949	=
B-intervention-participants	950	952	51
O	952	953	)
O	954	956	or
B-intervention	957	959	HD
O	960	961	(
O	961	962	n
O	963	964	=
B-intervention-participants	965	967	47
O	967	968	)
O	968	969	.

B-outcome	970	973	ORR
O	974	977	was
O	978	985	similar
O	986	992	across
O	993	997	dose
O	998	1006	regimens
O	1006	1007	:
B-iv-bin-percent	1008	1010	11
I-iv-bin-percent	1010	1011	.
I-iv-bin-percent	1011	1012	1
I-iv-bin-percent	1012	1013	%
O	1013	1014	,
B-iv-bin-percent	1015	1017	17
I-iv-bin-percent	1017	1018	.
I-iv-bin-percent	1018	1019	6
I-iv-bin-percent	1019	1020	%
O	1021	1024	and
B-iv-bin-percent	1025	1027	10
I-iv-bin-percent	1027	1028	.
I-iv-bin-percent	1028	1029	6
I-iv-bin-percent	1029	1030	%
O	1031	1034	for
O	1035	1037	AD
O	1037	1038	,
O	1039	1041	LD
O	1042	1045	and
O	1046	1048	HD
O	1048	1049	,
O	1050	1062	respectively
O	1062	1063	,
O	1064	1068	with
O	1069	1080	overlapping
O	1081	1091	confidence
O	1092	1101	intervals
O	1101	1102	.

B-outcome	1103	1106	TTP
I-outcome	1107	1110	and
I-outcome	1111	1114	CBR
O	1115	1119	were
O	1120	1124	also
O	1125	1132	similar
O	1133	1140	between
O	1141	1147	groups
O	1148	1149	(
B-outcome	1149	1155	median
I-outcome	1156	1159	TTP
O	1159	1160	:
B-iv-cont-median	1161	1162	6
I-iv-cont-median	1162	1163	.
I-iv-cont-median	1163	1164	0
O	1164	1165	,
B-iv-cont-median	1166	1167	7
I-iv-cont-median	1167	1168	.
I-iv-cont-median	1168	1169	5
O	1170	1173	and
B-iv-cont-median	1174	1175	6
I-iv-cont-median	1175	1176	.
I-iv-cont-median	1176	1177	0
I-iv-cont-median	1178	1184	months
O	1184	1185	,
O	1186	1198	respectively
O	1198	1199	;
B-outcome	1200	1203	CBR
O	1203	1204	:
B-iv-bin-percent	1205	1207	42
I-iv-bin-percent	1207	1208	.
I-iv-bin-percent	1208	1209	2
I-iv-bin-percent	1209	1210	%
O	1210	1211	,
B-iv-bin-percent	1212	1214	54
I-iv-bin-percent	1214	1215	.
I-iv-bin-percent	1215	1216	9
I-iv-bin-percent	1216	1217	%
O	1218	1221	and
B-iv-bin-percent	1222	1224	46
I-iv-bin-percent	1224	1225	.
I-iv-bin-percent	1225	1226	8
I-iv-bin-percent	1226	1227	%
O	1228	1231	for
O	1232	1234	AD
O	1234	1235	,
O	1236	1238	LD
O	1239	1242	and
O	1243	1245	HD
O	1245	1246	,
O	1247	1259	respectively
O	1259	1260	)
O	1260	1261	.

O	1262	1263	C
O	1263	1264	(
O	1264	1267	max
O	1267	1268	)
O	1269	1272	and
O	1273	1277	area
O	1278	1283	under
O	1284	1287	the
O	1288	1294	plasma
O	1295	1308	concentration
O	1308	1309	-
O	1309	1313	time
O	1314	1319	curve
O	1320	1324	were
O	1325	1329	dose
O	1330	1342	proportional
O	1343	1346	and
O	1347	1349	PK
O	1350	1356	steady
O	1357	1362	state
O	1363	1366	was
O	1367	1374	reached
O	1375	1382	earlier
O	1383	1387	with
O	1388	1390	LD
O	1391	1394	and
O	1395	1397	HD
O	1398	1402	than
O	1403	1407	with
O	1408	1410	AD
O	1410	1411	.

O	1412	1415	All
O	1416	1421	three
O	1422	1427	doses
O	1428	1432	were
O	1433	1437	well
O	1438	1447	tolerated
O	1447	1448	,
O	1449	1453	with
O	1454	1455	a
O	1456	1463	similar
O	1464	1471	adverse
O	1471	1472	-
O	1472	1477	event
O	1478	1485	profile
O	1486	1489	and
O	1490	1492	no
O	1493	1501	emerging
O	1502	1508	safety
O	1509	1517	concerns
O	1517	1518	.

O	1519	1530	Fulvestrant
O	1531	1533	AD
O	1533	1534	,
O	1535	1537	LD
O	1538	1541	and
O	1542	1544	HD
O	1545	1548	had
O	1549	1556	similar
O	1557	1565	efficacy
O	1566	1569	and
O	1570	1582	tolerability
O	1583	1591	profiles
O	1592	1594	in
O	1595	1609	postmenopausal
O	1610	1618	Japanese
O	1619	1624	women
O	1625	1629	with
O	1630	1632	ER
O	1632	1633	-
O	1633	1641	positive
O	1642	1650	advanced
O	1651	1657	breast
O	1658	1664	cancer
O	1664	1665	.
